Ilsung Is Co., Ltd.
003120.KS
Get informed when a big investor buys or sells
+ FollowMarket Cap$160.07B
Close$
Share Statistics
| Market cap | $160.07 Billion |
|---|---|
| Enterprise Value | $54.33 Billion |
| Dividend Yield | $1200.00 (5.37%) |
| Earnings per Share | $170 |
| Beta | -0.16 |
| Outstanding Shares | 7,162,047 |
Return
| Return on Equity | 1.46% |
|---|---|
| Return on Assets | 1.41% |
| Return on Invested Capital | -1.70% |
Valuation & Multiples
| P/E Ratio | 39.13 |
|---|---|
| PEG | -37.18 |
| Price to Sales | 2.37 |
| Price to Book Ratio | 0.41 |
| Enterprise Value to Revenue | 0.83 |
| Enterprise Value to EBIT | -8.39 |
| Enterprise Value to Net Income | 9 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Ilsung Is Co., Ltd.
224 employees
CEO: Seok-geun Yoon Ilsung Is Co., Ltd. is a South Korean pharmaceutical company established in 1961. The company specializes in the research, development, and manufacturing of medicines, with a historical focus on antibiotics. It also has products in areas...